Introduction
============

The endocannabinoid system consists of two compounds with amphipathic structure, 2-arachidonyl glycerol (2-AG) and anandamide (AEA), the enzymes that produce and degrade them, and two cannabinoid, CB~1~ and CB~2~, receptors (see [@B22] and references therein). Recent evidence presents the endocannabinoid system as one of the most relevant in mammals for homeostatic control of energy expenditure and temperature, and for regulating innate and acquired immunity and neural transmission. Cannabinoid receptors belong to the superfamily of G-protein-coupled receptors (GPCRs) and are reportedly coupled to the heterotrimeric G~i~ protein^[1](#fn01){ref-type="fn"}^, i.e., their activation leads to a decrease in the intracellular level of a second messenger, cAMP. Although CB~1~ receptors (CB~1~Rs) are mainly located in neurons of the central nervous system (CNS), their expression in glia has been described ([@B37]; [@B4]). In fact, CB~1~Rs are considered to be the most abundant GPCRs in the CNS and the targets of the Δ^9^-tetrahydrocannabinol (Δ^9^-THC), the main psychotropic component of *Cannabis sativa* L. CB~2~ receptor (CB~2~R), which soon after its identification was considered a prototypic peripheral receptor, is also expressed in the CNS, both in glia ([@B42]; [@B5]; [@B11]) and neurons of some specific brain regions such as cerebellum or *globus pallidus* ([@B19]; [@B36]). Heteromerization of CB~1~R/CB~2~R in the brain is a well-accepted phenomenon that further diversifies the physiological actions of endo- and exogenous cannabinoids ([@B6]; [@B36]). Although physiological relevance of this heteromer expression is not fully understood, evidence suggests potential in CNS-related drug discovery.

Apart from heteromerization, drug discovery efforts for cannabinoid receptors also involve the use of allosteric cannabinoid ligands. Whereas cannabinoids interact with the orthosteric receptor site, allosteric modulators bind to a topographically distinct binding site modifying receptor conformation and leading to novel properties and modes of action ([@B9]). In fact, allosteric modulators can impact on the affinity of the orthosteric binding pocket and also in the intracellular signaling responses, in either a positive or negative direction. To date, a number of allosteric cannabinoid receptor modulators have been reported for CB~1~R, e.g., lipoxin A4, ORG27569, PSNCBAM-1 or cannabidiol (CBD) ([@B28]; [@B21]; [@B27]).

CBD, the main non-psychoactive phytocannabinoid, exerts a wide range of cellular effects through the endocannabinoid system, as was indicated in a systematic review in 2015 ([@B25]). However, its mode of action is far from being understood. In some *in vitro* assays, CBD action has been linked to CB~2~Rs activation because some *in vivo* effects were blocked by the administration of a CB~2~R antagonist. Thus, [@B16], using AM630 as antagonist, reported that the weight gain-reducing effect of CBD apparently involved CB~2~Rs. In addition, the well-substantiated protective role of CBD in newborn hypoxia-ischemia correlates with CB~2~R expression ([@B7]; [@B2]; [@B18]; [@B29]). In other *in vitro* assays, CBD was shown as a high potency antagonist of CB~2~R expressed in CHO cells ([@B38]). Nevertheless, radioligand and/or GTPgammaS binding assays indicate that the compound does not bind with high affinity to either rat or human CB~2~Rs ([@B14]; [@B30]; [@B26]). At present, the idea that CBD actions are mediated by binding to serotonin 5-HT~1A~ receptors is favored. For instance, CBD affords protection against oxygen-glucose deprivation in a model of the blood--brain barrier by a mechanism involving 5-HT~1A~ and PPARγ receptors ([@B15]). Further behavioral studies also suggest that CBD may act via 5-HT~1A~ receptors ([@B34]; [@B3]; [@B23]; [@B33]; [@B10]; [@B35]). Such assumption is intriguing as the reported affinity of CBD binding to these serotonin receptors does not lie within the nanomolar high affinity range ([@B34]). More recently, some authors open new avenues in the therapeutic use of this phytocannabinoid. Thus, they seem to demonstrate that CBD was able to reduce the effect of 2-AG and Δ^9^-THC on CB~1~R internalization and PLCβ3 and ERK1/2 phosphorylation, proposing that CBD may act as a negative allosteric modulator of these receptors ([@B21]).

The aim of this work was to search for the possibility that CBD acts as an allosteric ligand of CB~2~R by checking whether it is able to modulate the binding and functional effect of CB~2~R agonists.

Materials and Methods {#s1}
=====================

Materials and Reagents
----------------------

For radioligand binding assays, \[^3^H\]-(R)-(+)-\[2,3-dihydro-5-methyl-3-(4-morpholinyl methyl)pyrrolo\[1,2,3-de\]-1,4-benzoxazin-6-yl\]-1-naphthalenylmethanone (\[^3^H\]-WIN 55,212-2) was purchased from PerkinElmer (Wellesley, MA, United States). CBD, WIN 55,212-2 mesylate and SR144528 were obtained from Tocris Bioscience (Bristol, United Kingdom). THC was obtained from THC Pharm (Frankfurt, Germany).

For non-radioactive binding assays, the Tag-lite labeling medium (TLB) was obtained from Cisbio Bioassays (LABMED, Cisbio Assays, Codolet, France). The Tb derivative of O6-benzylguanine was synthesized by Cisbio Bioassays and is commercialized as SNAP-Lumi4-Tb (SSNPTBC, Cisbio Assays, Codolet, France). CB~2~R agonist, 3-\[\[4-\[2-*tert*-butyl-1-(tetrahydropyran-4-ylmethyl)benzimidazol-5-yl\]sulfonyl-2-pyridyl\]oxy\]propan-1-amine (CM-157), conjugated to red-naltrexone fluorescent probe (red CB~2~R ligand) was developed by Cisbio Bioassays. The unlabeled compound was synthesized as described in [@B24] based on the information given in the WO2008003665 patent and in [@B40]. Stock solutions were prepared in DMSO. Aliquots of these stock solutions were kept frozen at -20°C until use. The plasmid encoding for the SNAP-tagged human CB~2~R used for transient transfection was obtained from Cisbio Bioassays (PSNAP-CB2, Cisbio Assays, Codolet, France). The white opaque 384-well plates were obtained from PerkinElmer (Wellesley, MA, United States).

Radioligand Binding Assays
--------------------------

### Cell Culture and Membrane Preparation

CHO cells stably expressing human CB~2~R (CHO-CB~2~R) (PerkinElmer, United States) were grown adherently and maintained in Ham's F12 medium containing 10% heat-inactivated fetal bovine serum (FBS), 100 units/mL penicillin/streptomycin and 0.4 mg/mL geneticin (G418) at 37°C in 5% CO~2~ humid atmosphere.

For membrane isolation, culture medium was removed and cells were washed with phosphate-buffered saline (PBS) and scraped off in ice-cold hypotonic buffer (5 mM Tris--HCl, 2 mM EDTA, pH 7.4). The cell suspension was homogenized with a Polytron and then centrifuged for 30 min at 40,000 × *g*. The membrane pellet was suspended in 50 mM Tris--HCl buffer (pH 7.4) containing 1 mM EDTA, 5 mM MgCl~2~, 0.5 mg/mL bovine serum albumin (BSA).

### Saturation Binding Experiments

\[^3^H\]-WIN 55,212-2 saturation binding experiments (specific activity 48 Ci/mmol, PerkinElmer) were performed incubating different concentrations of the radioligand (0.2--40 nM) in binding buffer (50 mM Tris--HCl, pH 7.4, 1 mM EDTA, 5 mM MgCl~2~) with membranes from CHO cells stably expressing the human CB~2~R (10 μg per sample) at 30°C. Non-specific binding was determined in the presence of 1 μM WIN 55,212-2. At the end of the incubation period (60 min) bound and free radioactivity were separated in a Brandel cell harvester (Brandel Instruments) by filtering the assay mixture through Whatman GF/B glass fiber filters. The filter-bound radioactivity was counted using a Packard Tri Carb 2810 TR scintillation counter (PerkinElmer, Wellesley, MA, United States).

### Association Binding Experiments

Association binding experiments for \[^3^H\]-WIN 55,212-2 were performed incubating three different concentrations (0.8, 1.6, and 3.2 nM) of the radioligand in binding buffer (50 mM Tris--HCl, pH 7.4, 1 mM EDTA, 5 mM MgCl~2~) with human CHO-CB~2~R cell membranes at 30°C. Non-specific binding was determined in the presence of 1 μM WIN 55,212-2. Free and bound radioligand were separated through filtration at multiple time points (from 1 to 50 min) to construct association kinetic curves.

### Dissociation Binding Experiments

The dissociation rate of \[^3^H\]-WIN 55,212-2 was determined by allowing 3 nM radioligand to reach equilibrium with human CHO-CB~2~R cell membranes at 30°C for 60 min. To start dissociation, WIN 55,212-2 (10 μM final concentration) was added in order to occupy binding sites as they became available, thereby preventing re-association. The amount of radioactivity that remained bound to the receptor was determined by filtration harvesting and scintillation counting at different time points (from 0 to 50 min).

### Competition Binding Experiments

Competition binding experiments were performed incubating 3 nM \[^3^H\]-WIN 55,212-2 and different concentrations of the tested compounds with membranes obtained from CHO-CB~2~R cells (10 μg protein per sample) for 60 min at 30°C. Non-specific binding was determined in the presence of 1 μM WIN 55,212-2. Bound and free radioactivity were separated by filtering the assay mixture through Whatman GF/B glass fiber filters using a Brandel cell harvester. The filter-bound radioactivity was counted using a Packard Tri Carb 2810 TR scintillation counter (PerkinElmer).

Non-radioligand Binding Assays
------------------------------

### Cell Line Cultures and Transfection

Human embryonic kidney 293T (HEK-293T) cells were grown in DMEM supplemented with 2 mM [L]{.smallcaps}-glutamine, 1 mM sodium pyruvate, 100 units/mL penicillin/streptomycin, and 5% (v/v) FBS (all supplements were from Invitrogen, Paisley, Scotland, United Kingdom). Cells were maintained at 37°C in a humidified atmosphere of 5% CO~2~ and were passaged, with enzyme-free cell dissociation buffer (13151-014, Gibco^®^, Thermo Fisher Scientific, Waltham, MA, United States), when they were 80--90% confluent, i.e., approximately twice a week.

For fluorescent ligand-binding assays, HEK-293T cells growing in 25-cm^2^ flasks were transiently transfected with the SNAP-CB~2~R plasmid cloned in pcDNA3.1 by the Lipofectamine 2000 method (11668-019, Invitrogen, Thermo Fisher Scientific, Waltham, MA, United States). When reaching 60% confluence, cell medium was removed and replaced by 4 mL of fresh medium. In parallel, a transfection mix containing 8 μg of plasmid, 20 μL of Lipofectamine 2000, and 1 mL of Opti-MEM without serum (51985-026, Gibco^®^, Thermo Fisher Scientific, Waltham, MA, United States) final volume was incubated for 20 min at room temperature prior to being added on cells. The transfected-cell culture flask was incubated at 37°C under 5% CO~2~ for 24 h.

### Labeling of Cells Expressing SNAP-Tagged CB~2~R

Cell culture medium was removed from the 25-cm^2^ flask and 100 nM SNAP-Lumi4-Tb, previously diluted in 3 mL of TLB 1×, was added to the flask and incubated for 1 h at 37°C under 5% CO~2~ atmosphere in a cell incubator. After that, cells were washed four times with 2 mL of TLB 1× to remove the excess of SNAP-Lumi4-Tb, detached with enzyme-free cell dissociation buffer, centrifuged 5 min at 1,500 rpm and collected in 1 mL of TLB 1×. Tag-lite-based binding assays were performed 24 h after transfection. Densities from 2,500 to 3,000 cells per well were used to carry out binding assays in suspension in white opaque 384-well plates.

### Competition and Saturation Binding Assays

For competition binding assay, red CB~2~R ligand (labeled CM-157) and CBD were diluted in TLB 1×. HEK-293T cells transiently expressing Tb-labeled SNAP-CB~2~R were incubated with 100 nM red CB~2~R ligand, in the presence of increasing concentrations (0--10 μM range) of CBD. In plates containing 10 μL of labeled cells, 5 μL of TLB 1× or 5 μL of CBD was added prior to the addition of 5 μL of fluorescent ligand. Plates were then incubated for at least 2 h at room temperature before signal detection.

Saturation binding experiments were performed by incubating HEK-293T cells transiently expressing Tb-labeled SNAP-CB~2~R with increasing concentrations of the red CB~2~R ligand (range, 0--300 nM final) in TLB 1×. For each concentration, non-specific binding was determined by adding 100 μM unlabeled CB~2~R ligand. In the plates containing 10 μL labeled cells, 5 μL of 100 μM unlabeled CB~2~R ligand or TLB 1× was added, followed by the addition of 5 μL of increasing concentrations of the red CB~2~R ligand. Plates were incubated for 2 h at room temperature before signal reading.

Signal was detected using an EnVision microplate reader (PerkinElmer, Waltham, MA, United States) equipped with a FRET optic module allowing donor excitation at 337 nm and signal collection at both 665 and 620 nm. A frequency of 10 flashes/well was selected for the xenon flash lamp excitation. The signal was collected at both 665 and 620 nm using the following time-resolved settings: delay, 150 μs; integration time, 500 μs. HTRF ratios were obtained by dividing the acceptor signal (665 nm) by the donor signal (620 nm) and multiplying this value by 10,000. The 10,000-multiplying factor is used solely for the purpose of easier data handling.

### Data Analysis

Data were then analyzed using Prism 6 (GraphPad Software, Inc., San Diego, CA, United States). *K~D~* values were obtained from saturation curves of the specific binding. Specific binding was determined by subtracting the non-specific HTRF ratio from the total HTRF ratio. *K~D~* and *B*~max~ values in saturations experiments were calculated assuming one binding site in monomeric receptor. Unlike in radioligand binding assays, *B*~max~ values obtained from HTRF data do not reflect absolute values of receptor binding sites; they are, however, useful for comparison purposes. Finally, *K~i~* values were determined according to the Cheng and Prusoff equation ([@B8]). Signal-to-background (S/B ratio) calculations were performed by dividing the mean of the maximum value (μ~max~) by that of the minimum value (μ~min~) obtained from the sigmoid fits.

cAMP Determination
------------------

Two hours before initiating the experiment, growth medium was replaced by serum-free DMEM. Then, HEK-293T cells transiently expressing CB~2~R or GPR55 were detached and resuspended in growing medium containing 50 μM zardaverine and plated in 384-well microplates (2,500 cells/well), pretreated (15 min) with the corresponding antagonists---or vehicle---and stimulated with agonists (15 min) before adding 0.5 μM forskolin or vehicle. Readings were performed after 15 min of incubation at 25°C. HTRF measures were performed using the Lance Ultra cAMP kit (PerkinElmer, Waltham, MA, United States). Fluorescence at 665 nm was analyzed on a PHERAstar Flagship microplate reader equipped with an HTRF optical module (BMG Lab Technologies, Offenburg, Germany).

ERK1/2 Phosphorylation
----------------------

To determine ERK1/2 phosphorylation, 40,000 HEK-293T-CB~2~R cells/well were plated in transparent Deltalab 96-well microplates and kept at the incubator for 24 h. Two to four hours before the experiment, the medium was replaced by serum-free DMEM. Then, cells were treated with 100 nM JWH133 and increasing concentrations of CBD in serum-free medium at 25°C for 7 min. Cells were then washed twice with cold PBS before addition of lysis buffer (20 min treatment). Ten microliters of each supernatant were placed in white ProxiPlate 384-well microplates and ERK1/2 phosphorylation was determined using AlphaScreen^®^SureFire^®^ kit (PerkinElmer) following the instructions of the supplier and using an EnSpire^®^ Multimode Plate Reader (PerkinElmer, Waltham, MA, United States).

Statistical Analysis
--------------------

The data in graphs are the mean ± SEM. Statistical analysis was performed with SPSS 18.0 software. The test of Kolmogorov--Smirnov with the correction of Lilliefors was used to evaluate normal distribution and the test of Levene to evaluate the homogeneity of variance. Significance was analyzed by one-way ANOVA, followed by Bonferroni's multiple comparison *post hoc* test. Significant differences were considered when *p* \< 0.05.

Results
=======

Radioligand-Based Assays of Agonist Binding to Human CB~2~R Expressed in Isolated Membranes
-------------------------------------------------------------------------------------------

The effect of CBD on agonist binding to CB~2~R was first tested using a classical radioligand-binding assay and membranes isolated from CHO cells stably expressing human CB~2~R and incubated with \[^3^H\]-WIN 55,212-2. Data obtained from binding isotherms using increasing WIN 55,212-2 concentrations lead to a monophasic saturation curve with a *K~D~* value of 3.4 ± 0.2 nM (**Figures [1A,B](#F1){ref-type="fig"}**), which fits with the values reported in the literature ([@B26]). Kinetic experiments of association of \[^3^H\]-WIN 55,212-2 (Supplementary Figure [1A](#SM1){ref-type="supplementary-material"}) and its dissociation by excess unlabeled WIN 55,212-2 (Supplementary Figure [1B](#SM1){ref-type="supplementary-material"}) showed *k*~on~ and *k*~off~ values whose quotient provides an equilibrium constant that is in agreement with the *K~D~* value calculated from saturation data.

![Saturation curves from radioligand binding. Saturation curve **(A)** and relative Scatchard plot **(B)** of \[^3^H\]-WIN 55,212-2 binding on membranes from CHO cells stably expressing human CB~2~R. Data are expressed as the mean ± SEM of three independent experiments performed in duplicate.](fphar-08-00744-g001){#F1}

Competition and Saturation Assays in the Presence of CBD
--------------------------------------------------------

Competition of 3 nM \[^3^H\]-WIN 55,212-2 with increasing concentrations of the "cold" compound led to a *K~i~* value of 3.6 ± 0.3 nM, well in agreement with the *K~D~* (**Figure [2A](#F2){ref-type="fig"}**). The *K~i~* value, when CBD was used as competitor, was in the micromolar range (4.2 ± 0.3 μM). The same phenomenon was observed with increasing concentrations of THC, *K~i~* value of 3.3 ± 0.2 μM (**Figure [2A](#F2){ref-type="fig"}**). Competition curves in radioligand binding assays were clearly monophasic, i.e., no significant effect was observed at submicromolar CBD concentrations.

![Competition curves in radioligand- and HTRF-based assays. **(A)** Competition curves of specific 3 nM \[^3^H\]-WIN 55,212-2 binding by unlabeled (0--10 μM) WIN 55,212-2, CBD and THC. **(B)** Competition curve of specific binding of 100 nM red CB~2~R ligand with increasing concentrations of CBD (0--10 μM) measured by HTRF. Data represent the mean ± SEM of a representative experiment (*n* = 4). HTRF ratio = (665 nm acceptor signal/620 nm donor signal) × 10,000.](fphar-08-00744-g002){#F2}

Similar competition experiments were performed using 100 nM of a fluorescent CB~2~R agonist and a recently described homogeneous non-radioactive method performed in living cells expressing the human version of the receptor (details in [@B24]). Competition of binding to the orthosteric center of the fluorescent agonist by CBD was partial but consistent, occurring at low nanomolar CBD concentrations (circa 25% reduction and IC~50~ in the 2--8 nM range) (**Figure [2B](#F2){ref-type="fig"}**). In order to obtain more insight on the nature of CBD binding to CB~2~R, saturation experiments were performed in HEK-293T cells expressing SNAP-CB~2~R and using increasing concentrations of red CB~2~R ligand in the presence of 10 or 100 nM CBD. Data showed that CBD decreases the affinity of the orthosteric CB~2~R ligand, whereas maximum binding (*B*~max~) was not modified (**Figure [3A](#F3){ref-type="fig"}** and **Table [1](#T1){ref-type="table"}**). For comparison, a similar experiment was performed using 10 and 100 nM concentrations of SR144528, a CB~2~R antagonist that reportedly binds to the orthosteric site ([@B32]; [@B13]). The *K~D~* value (**Figure [3B](#F3){ref-type="fig"}**) did not change when this selective CB~2~R antagonist was used. Interestingly, the antagonist reduced *B*~max~ values thus suggesting that it behaves, in binding to living cells, in an irreversible-like fashion. Taken together, the results were suggestive of CBD binding to an allosteric site at nanomolar concentrations while requiring higher concentrations (in the micromolar range) to bind to the orthosteric site.

![Saturation curves measured by HTRF. Saturation binding experiments of fluorescent CB~2~R ligand (CM-157) in HEK-293T cells transiently transfected with SNAP-CB~2~R in the absence or presence of 10 nM (squares) or 100 nM (triangles) CBD **(A)**, or in the absence or presence of 10 nM (squares) or 100 nM (triangles) SR144528 **(B)**. Specific binding signals were calculated by subtracting the non-specific signal determined in the presence of 100 μM unlabeled CB~2~R ligand. Data represent the mean ± SEM of a representative experiment (*n* = 4). HTRF ratio = (665 nm acceptor signal/620 nm donor signal) × 10,000.](fphar-08-00744-g003){#F3}

###### 

Red CB~2~R ligand (CM-157) binding parameters, in the absence and presence of CBD. Data represent the mean ± SEM of five independent experiments performed in quadruplicate.

  Condition                        *K~D~* (nM)   *B*~max~ (RU)^a,b^
  -------------------------------- ------------- --------------------
  Red CB~2~R ligand                60 ± 10       3,480 ± 210
  Red CB~2~R ligand + 10 nM CBD    82 ± 28       3,060 ± 360
  Red CB~2~R ligand + 100 nM CBD   160 ± 20^∗^   3,380 ± 210

a

RU, relative unit.

b

B

max

parameter does not indicate the actual level of binding sites, but it may be used for comparative purposes.

∗

Significant differences analyzed by one-way ANOVA and Bonferroni's multiple comparison

post hoc

tests (

∗

p

\< 0.05

versus

absence of CBD).

CBD Modulates CB~2~R Signaling
------------------------------

CBD action has been often associated to CB~2~R expression but its binding to the orthosteric site of the receptor is seemingly unspecific; we hypothesized that it might act as allosteric modulator. To test the hypothesis, we first confirmed that the compound (concentration range: 1--1,000 nM) did not significantly engage any G-protein-coupled signal in HEK-293T cells expressing the human version of CB~2~R (**Figure [4A](#F4){ref-type="fig"}**). CBD was also tested in cells expressing the human version of GPR55, a GPCR that may bind cannabinoids, and the results were similar to those in cells expressing the CB~2~R (**Figure [4C](#F4){ref-type="fig"}**). We next tested whether CBD could affect the action of the selective CB~2~R agonist, JWH133, on forskolin-induced intracellular cAMP levels. The results show that the decrease in cAMP levels induced by 100 nM JWH133 was dose-dependently blocked by CBD (*F*~4,71~ = 15, *p* \< 0.001) (**Figure [4B](#F4){ref-type="fig"}**). IC~50~ of the CBD effect was 3 ± 0.4 nM. Again, the response of HEK-293T transiently transfected with GPR55 to the combined treatment with CBD and JWH133 was not significantly different than that achieved by CBD alone (**Figure [4D](#F4){ref-type="fig"}**). Similar experiments were undertaken but using ERK1/2 phosphorylation as a read-out. The results in **Figure [5](#F5){ref-type="fig"}** show that significant ERK1/2 phosphorylation triggered by 100 nM JWH133 was dose-dependently blocked by CBD (*F*~4,10~ = 11, *p* \< 0.01) with an IC~50~ of 29 ± 0.3 nM. These signaling data showed that CBD was able to negatively modulate CB~2~R signaling at concentrations lower to those required to significantly bind to the orthosteric center of the receptor.

![Dose-response effect of CBD on cAMP levels. HEK-293T cells were transiently transfected with cDNA encoding for human CB~2~ **(A,B)** or GPR55 **(C,D)** receptors. The effect of CBD on the decrease by JWH133 of forskolin-induced cAMP levels is displayed as a dose-response curve **(B)**. Cells were treated (15 min) with different concentrations of CBD in the absence or presence of 100 nM JWH133, a selective CB~2~R agonist and, finally, with 0.5 μM forskolin (15 min). Agonist-induced reduction in cAMP was 31 ± 4 and data (mean ± SEM) are given in percentage of the 500 nM forskolin-induced cAMP concentration. Significant differences were analyzed on data from seven different experiments; one-way ANOVA and Bonferroni's multiple comparison *post hoc* test were used for statistical analysis (*F*~4,71~ = 15, *p* \< 0.001) (^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001, *versus* 0 nM CBD treatment).](fphar-08-00744-g004){#F4}

![Dose-response effect of CBD on ERK1/2 phosphorylation. HEK-293T cells transfected with human CB~2~R were stimulated with 100 nM of JWH133 agonist in the presence of CBD. ERK1/2 phosphorylation levels were determined by using AlphaScreen^®^SureFire^®^ kit. Data are normalized and expressed as a percentage of over-basal response (mean ± SEM). Significant differences were analyzed on data from three different experiments; one-way ANOVA and Bonferroni's multiple comparison *post hoc* test were used for statistical analysis (*F*~4,10~ = 11, *p* \< 0.01) (^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, *versus* 0 nM CBD treatment).](fphar-08-00744-g005){#F5}

Discussion
==========

The results reported confirm that nanomolar CBD concentrations are not able to displace the binding of WIN 55,212-2 to the orthosteric center of the CB~2~R in radioligand binding assays. The binding data using the non-radioactive homogeneous method performed in living cells showed, however, that the binding of the fluorescent orthosteric ligand to HEK-293T cells expressing CB~2~R was slightly but consistently modified by nanomolar concentrations of CBD. The most plausible interpretation of these data is an allosteric effect disclosed in HTRF-mediated binding assays and a very small difference in the binding mode of radiolabeled WIN 55,212-2 or fluorescence-labeled CM-157 to CB~2~R. Unfortunately, WIN 55,212-2 could not be used in non-radioactive assays as it non-specifically interacted (for unknown reasons) with the HTRF probes. We found the same non-specific interaction with the fluorescent labeled CBD (data not shown). Structural differences related to the binding of different agonists that may be revealed by HTRF have been discussed elsewhere ([@B24]). In that paper, the extensively studied ligand AM630 displayed a biphasic curve on competing with CM-157 binding to CB~2~R. The results here presented could fit with CBD binding to the high-affinity sites disclosed using AM630 but not to the low-affinity ones. Alternatively, AM630 reduction of high-affinity binding, which occurred at subnanomolar concentrations of AM630, could be due to the same mechanism than that of CBD. In fact, the two compounds displayed on HTRF-based binding assays two components, one at low concentrations, and another at higher concentrations.

A further piece of information from results using the selective orthosteric CB~2~R antagonist, SR144528, was the irreversible-like behavior when performing HTRF-based binding to living cells. In binding or functional assays using isolated membranes or tissue extracts from CB~2~R-expressing cells, the antagonist acts in a reversible fashion ([@B32]; [@B13]). CBD seemingly allosteric action was detectable by functional experiments (cAMP and pERK1/2 assays) in which we show that the effect of a selective CB~2~R agonist was modulated by CBD at physiologically relevant (nanomolar) concentrations. The participation of a third component, acting as mediator of CBD effects on CB~2~R signaling cannot be ruled out.

In the absence of consensus data showing a direct interaction between CBD and cannabinoid receptors, only indirect evidence suggests that CBD could be a modulator of endocannabinoid signaling. Accordingly, CBD was suspected to act as allosteric modulator of cannabinoid receptors ([@B31]). In agreement with this possibility, [@B21] were the first to suggest that CBD acts as allosteric modulator of CB~1~R; although no binding studies were performed, the allosteric site in the receptor was mapped to two cysteine residues in the N-terminal end. Therefore, CBD reduces both potency and efficacy of endogenous and exogenous cannabinoids on ERK1/2-PLCβ3-dependent signaling in an heterologous expression system, and in cells endogenously expressing the receptor. Authors also reported that CBD affects the kinetics of β-arrestin recruitment and CB~1~R internalization.

Allosteric modulators of natural origin do usually provide negative modulation in both enzymology and pharmacology. Allosteric action was negative in both the results reported by [@B21] on CB~1~R-mediated signaling and ours on CB~2~R-mediated signaling; the allosteric effect in both cases seems to be, at least in part, mediated by a CBD-induced decrease in affinity of the orthosteric agonist (**Table [1](#T1){ref-type="table"}**). One interesting possibility would be that cannabinoids may produce effect of allosteric nature on a variety of GPCRs. In support of this option, [@B20] showed that the endocannabinoid 2-AG acts as an allosteric modulator of the human adenosine A~3~ receptor. Adenosine A~3~ receptors are coupled to a heterotrimeric G~i~ protein and the action of 2-AG resulted in a decrease in the potency of agonists and in the basal signaling of this adenosine receptor subtype. Their negative effects on the receptor-mediated cAMP response are similar to those reported here for CBD acting on CB~2~R. CBD is also described as an allosteric modulator of μ- and ∂-opioid receptors ([@B39]; [@B17]). Both Δ^9^-THC and CBD accelerate the dissociation of opioids from the receptors although the function of CBD on opioid receptors was not studied ([@B17]).

Ligand-gated receptors are also affected by CBD. Indeed, CBD inhibits currents mediated by serotonin 5-HT~3A~ receptors expressed in *Xenopus laevis* oocytes ([@B41]). Higher CBD concentrations, in the micromolar range, are able to allosterically modulate ligand-gated glycine receptors impacting on the role of glycine in postsynaptic transmission in the adult spinal cord ([@B1]; [@B12]). The interacting motif is mapped to Ser^276^ of the alpha1 subunit of the receptor ([@B12]), thus seemingly different from the binding motif reported for CB~1~R ([@B21]). Homologous residues to those in the CB~1~R sequence are not present in the CB~2~R one and, therefore, the putative binding site may not be located in the N-terminal domain of the CB~2~R; in fact, the putative N-terminal domain is much shorter for CB~2~ than for CB~1~ receptors (33 *versus* 116 amino acids^[2](#fn02){ref-type="fn"}^). Elucidation of the structure for the CB~1~R rises hope for a similar achievement for CB~2~R and, subsequently, for detecting allosteric sites that would help in designing novel drug discovery approaches targeting cannabinoid receptors. The N-terminal domain of the A~3~ receptor is also too short to be involved in the mode of action of 2-AG. Human μ and ∂ opioid receptors have longer N-terminal domains, 68 and 47, respectively, but there is no obvious homology between them. The two cysteine residues present in the N-terminal end of CB~1~R and that putatively conform a CBD binding site are not present in the N-terminal domain of ∂-opioid receptors. In summary, further experimental effort is needed to identify common motives for endocannabinoid action on ligand-gated and GPCRs, or to identify molecules interacting with these receptors and acting as mediators of the allosteric-like effect disclosed by CBD. Finding CBD binding motives in cannabinoid receptors or non-GPCR CBD targets would help in understanding some of the actions reported for endocannabinoids and for natural cannabinoids such as THC and CBD.

GPCRs constitute the target of 40--45% of current medicines that act, as agonists or antagonists, via the orthosteric center. The discovery of GPCR allosteric modulators or of modulators of signaling at concentrations 1--2 orders of magnitude below the IC~50~ values obtained in competing with the binding of orthosteric compounds, opens new perspectives for therapeutic benefit.
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AEA

:   anandamide

2-AG

:   2-arachidonyl glycerol

CBD

:   cannabidiol

CB~1~R

:   cannabinoid receptor subtype 1

CB~2~R

:   cannabinoid receptor subtype 2

CNS

:   central nervous system

GPCR

:   G-protein-coupled-receptor

HTRF

:   homogenous time-resolved fluorescence resonance energy transfer

Δ^9^-THC

:   Δ^9^-tetrahydrocannabinol

TR-FRET

:   time-resolved fluorescence resonance energy transfer
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